文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Insights on Multiple Myeloma Treatment Strategies.

作者信息

Mateos María-Victoria, Ludwig Heinz, Bazarbachi Ali, Beksac Meral, Bladé Joan, Boccadoro Mario, Cavo Michele, Delforge Michel, Dimopoulos Meletios A, Facon Thierry, Geraldes Catarina, Goldschmidt Hartmut, Hájek Roman, Hansson Markus, Jamroziak Krzysztof, Leiba Merav, Masszi Tamás, Mendeleeva Larisa, O'Dwyer Michael, Plesner Torben, San-Miguel Jesús F, Straka Christian, van de Donk Niels W C J, Yong Kwee, Zver Samo, Moreau Philippe, Sonneveld Pieter

机构信息

Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (CAUSA/IBSAL), Salamanca, Spain.

Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria.

出版信息

Hemasphere. 2018 Dec 27;3(1):e163. doi: 10.1097/HS9.0000000000000163. eCollection 2019 Feb.

DOI:10.1097/HS9.0000000000000163
PMID:31723802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6745941/
Abstract

The introduction of new agents and management strategies over the past decade has resulted in a major step change in treatment outcomes with deepening responses and increased survival for patients with multiple myeloma. In daily clinical practice, healthcare professionals are now faced with challenges including, optimal treatment sequencing and changing treatment goals. In light of this, a group of experts met to discuss diagnostic and treatment guidelines, examine current clinical practice, and consider how new clinical trial data may be integrated into the management of multiple myeloma in the future.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5968/6745941/23381e79d8b4/hs9-3-e163-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5968/6745941/23381e79d8b4/hs9-3-e163-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5968/6745941/23381e79d8b4/hs9-3-e163-g001.jpg

相似文献

[1]
Insights on Multiple Myeloma Treatment Strategies.

Hemasphere. 2018-12-27

[2]
The future of Cochrane Neonatal.

Early Hum Dev. 2020-11

[3]
Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma.

Clin Adv Hematol Oncol. 2011-4

[4]
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.

Hematology Am Soc Hematol Educ Program. 2013

[5]
Current and emerging treatments for multiple myeloma.

J Manag Care Pharm. 2008-9

[6]
Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects.

Front Med (Lausanne). 2021-2-25

[7]
Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients.

Semin Oncol Nurs. 2017-8

[8]
Clinical management of myeloma--state of the art.

Cancer Treat Rev. 2010-5

[9]
[Imaging in smoldering (asymptomatic) multiple myeloma. Past, present and future].

Radiologe. 2014-6

[10]
The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.

JBI Libr Syst Rev. 2009

引用本文的文献

[1]
abnormalities identified by fluorescence hybridization during follow-up confer poor prognosis in Chinese multiple myeloma.

Front Med (Lausanne). 2025-3-5

[2]
Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection.

Blood Cancer J. 2025-2-27

[3]
A real-world study on the impact of infection load on mortality in multiple myeloma patients in Finland.

Ann Hematol. 2025-4

[4]
Autophagy-related mechanisms for treatment of multiple myeloma.

Cancer Drug Resist. 2023-12-25

[5]
Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.

Biomolecules. 2023-11-7

[6]
Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients - real world evidence analysis.

Ann Hematol. 2023-6

[7]
Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany.

BMC Cancer. 2023-4-6

[8]
Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies.

Pharmaceuticals (Basel). 2023-1-12

[9]
PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed/refractory multiple myeloma patients.

Eur J Med Res. 2022-12-19

[10]
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma.

EJHaem. 2020-11-8

本文引用的文献

[1]
Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.

Haematologica. 2020-12-1

[2]
Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial.

Hemasphere. 2020-8-12

[3]
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).

Leukemia. 2020-2-5

[4]
CARs and other T cell therapies for MM: The clinical experience.

Best Pract Res Clin Haematol. 2018-6

[5]
Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.

Leukemia. 2018-2-2

[6]
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.

Future Oncol. 2017-12-22

[7]
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

N Engl J Med. 2017-12-12

[8]
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Blood. 2017-11-17

[9]
New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

J Blood Med. 2017-8-22

[10]
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

Blood. 2017-8-28

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索